Cytosorbents (CTSO) Research & Development (2010 - 2026)

Cytosorbents (CTSO) has reported Research & Development for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 15.13% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $4.6 million (down 31.44% YoY), and the FY2025 full-year result was $5.1 million, down 33.15% from the prior year.
• Research & Development improved to $1.5 million in Q2 2026 per CTSO's latest filing, from $1.0 million in the prior quarter.
• Across five years, Research & Development topped out at $4.2 million in Q1 2022 and bottomed at $918000.0 in Q3 2025.
• Historically, Research & Development has averaged $2.5 million across 5 years, with a median of $2.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development jumped 85.95% in 2022, then tumbled 58.6% in 2024.
• Over 5 years, Research & Development stood at $3.4 million in 2022, then grew by 16.46% to $4.0 million in 2023, then tumbled by 49.14% to $2.0 million in 2024, then sank by 38.31% to $1.2 million in 2025, then increased by 16.89% to $1.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.5 million, $1.0 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.